Kiin Bio: Accelerating drug discovery with Virtual Scientists (3-mo free access for SBC companies)

​We are pleased to invite you to an exclusive session hosted by Kiin Bio, the SBC-partner that can accelerate drug discovery through Connected Scientific Intelligence.

​Drug discovery today remains highly complex and fragmented, requiring significant time, cost, and coordination across teams. At Kiin Bio, they are rethinking this paradigm with KiinOS: a unified, AI-native platform orchestrated by Virtual Scientists that connects experiments, insights, and decisions into one intelligent workflow, bringing teams together and enabling seamless collaboration.

​Already working with leading biotech and pharmaceutical organisations across the UK and Europe, during this interactive session the Kiin team will show how they integrate seamlessly with your current processes. As partner of SBC, every SBC-based company can access their platform for free (3-month, no string attached).

​Agenda:

• ​11.30 - Discover how Kiin Bio accelerates your processes
  Overview on how Kiin is redefining drug discovery as a connected, end-to-end system
  

• ​12.00 - Live demo of KiinOS on specific use-cases
  See how the platform unifies experimental execution, insight generation, and decision-making, helping teams move faster from target to clinic
  

• ​12.30 - Networking Lunch
  

• ​13.00 - 15.30 (optional)
  Book a dedicated 1:1 session (30min) with Kiin Bio team to dive deeper into your organisation’s bottlenecks and identify where KiinOS can create immediate value

​Upon registration to the event you'll be able to:

• ​Vote the use cases you'd like to see covered during the session

• ​Book your 121 session with Kiin Bio's team

​Platform use cases:

• ​Commercial Intelligence
  Competitor intelligence, clinical trial and patent review
  

• ​Target Identification
  Literature and biological data exploration to identify targets and indications
  

• ​Biomarker Validation
  Analytics and bioinformatics pipelines to clean, harmonise, and interpret data
  

• ​Lab Validation
  Protocol discovery & optimisation, CRO identification, and reagent sourcing
  

• ​Hit ID & Lead Optimisation
  Computational chemistry workflows for small molecules
  

• ​Clinical Trials Analytics
  Analysis of trial results, patient stratification, and cohort identification
  

• ​Structure based drug discovery
  Leverage tools such as Boltz to co-fold proteins and predict binding affinity